185 related articles for article (PubMed ID: 37691397)
41. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
42. [Merkel cell carcinoma: cutaneous manifestation of a highly malignant pre-/pro-B cell neoplasia? : Novel concept about the cellular origin of Merkel cell carcinoma].
Sauer CM; Chteinberg E; Rennspiess D; Kurz AK; Zur Hausen A
Hautarzt; 2017 Mar; 68(3):204-210. PubMed ID: 28194491
[TBL] [Abstract][Full Text] [Related]
43. Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives.
Zaggana E; Konstantinou MP; Krasagakis GH; de Bree E; Kalpakis K; Mavroudis D; Krasagakis K
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612102
[TBL] [Abstract][Full Text] [Related]
44. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
[TBL] [Abstract][Full Text] [Related]
45. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
46. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.
Femia D; Prinzi N; Anichini A; Mortarini R; Nichetti F; Corti F; Torchio M; Peverelli G; Pagani F; Maurichi A; Mattavelli I; Milione M; Bedini N; Corti A; Di Bartolomeo M; de Braud F; Pusceddu S
Target Oncol; 2018 Oct; 13(5):567-582. PubMed ID: 30073632
[TBL] [Abstract][Full Text] [Related]
47. Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies.
Villani A; Fabbrocini G; Costa C; Carmela Annunziata M; Scalvenzi M
Dermatol Ther (Heidelb); 2019 Jun; 9(2):209-222. PubMed ID: 30820877
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.
Gallo M; Guarnotta V; De Cicco F; Rubino M; Faggiano A; Colao A;
J Cancer Res Clin Oncol; 2019 Feb; 145(2):429-443. PubMed ID: 30617553
[TBL] [Abstract][Full Text] [Related]
49. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
50. Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.
Tabachnick-Cherny S; Pulliam T; Rodriguez HJ; Fan X; Hippe DS; Jones DC; Moshiri AS; Smythe KS; Kulikauskas RM; Zaba LC; Paulson KG; Nghiem P
Clin Cancer Res; 2024 Mar; 30(6):1189-1199. PubMed ID: 37851052
[TBL] [Abstract][Full Text] [Related]
51. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
Harms PW; Harms KL; Moore PS; DeCaprio JA; Nghiem P; Wong MKK; Brownell I;
Nat Rev Clin Oncol; 2018 Dec; 15(12):763-776. PubMed ID: 30287935
[TBL] [Abstract][Full Text] [Related]
52. Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma.
Turshudzhyan A; Hadfield M; Grant-Kels J
Melanoma Res; 2021 Oct; 31(5):421-425. PubMed ID: 34284460
[TBL] [Abstract][Full Text] [Related]
53. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.
Spada F; Bossi P; Caracò C; Sileni VC; Dei Tos AP; Fazio N; Grignani G; Maio M; Quaglino P; Queirolo P; Ascierto PA;
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35701070
[TBL] [Abstract][Full Text] [Related]
54. Advanced Merkel cell carcinoma-A focus on medical drug therapy.
Wollina U; Koch A; Cardoso JC
Dermatol Ther; 2020 Jul; 33(4):e13675. PubMed ID: 32447821
[TBL] [Abstract][Full Text] [Related]
55. An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy.
Fojnica A; Ljuca K; Akhtar S; Gatalica Z; Vranic S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894451
[TBL] [Abstract][Full Text] [Related]
56. Targeting the epigenetic addiction of Merkel cell carcinoma.
Mauri F; Blanpain C
EMBO Mol Med; 2020 Nov; 12(11):e13347. PubMed ID: 33063436
[TBL] [Abstract][Full Text] [Related]
57. Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma.
Temblador A; Topalis D; Andrei G; Snoeck R
Tumour Virus Res; 2022 Dec; 14():200244. PubMed ID: 36007768
[TBL] [Abstract][Full Text] [Related]
58. Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma.
Hanna GJ; Kacew AJ; Tanguturi AR; Grote HJ; Vergara V; Brunkhorst B; Rabinowits G; Thakuria M; LeBoeuf NR; Ihling C; DeCaprio JA; Lorch JH
Front Med (Lausanne); 2020; 7():198. PubMed ID: 32582722
[No Abstract] [Full Text] [Related]
59. Merkel cell carcinoma: Do you know your guidelines?
Miles BA; Goldenberg D;
Head Neck; 2016 May; 38(5):647-52. PubMed ID: 26716756
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases.
Baltazar D; Zeitouni N; Patel N; Moser J
J Drugs Dermatol; 2024 Feb; 23(2):e57-e59. PubMed ID: 38306125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
